Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
Condition(s):Metastatic Neuroendocrine TumorsLast Updated:June 29, 2011Completed
Hide Studies Not Open or Pending
Condition(s):Metastatic Neuroendocrine TumorsLast Updated:June 29, 2011Completed
Condition(s):Neuroendocrine NeoplasmLast Updated:March 6, 2024Active, not recruiting
Condition(s):Advanced Neuroendocrine Tumors of Pancreatic OriginLast Updated:July 1, 2015Completed
Condition(s):Neuroendocrine Tumors; Neuroendocrine Carcinoma; Temozolomide; CapecitabineLast Updated:December 6, 2022Completed
Condition(s):Neuroendocrine Tumors With MetastasisLast Updated:June 1, 2016Unknown status
Condition(s):Neuroendocrine TumoursLast Updated:November 5, 2020Completed
Condition(s):Gastroenteropancreatico Tumors; Neuroendocrine Tumors; Neuroendocrine NeoplasmsLast Updated:February 20, 2024Recruiting
Condition(s):Neuroendocrine Tumors; Neuroendocrine Carcinoma; Neuroendocrine CancerLast Updated:March 26, 2024Active, not recruiting
Condition(s):Pancreatic Neuroendocrine TumorLast Updated:December 26, 2019Completed
Condition(s):Neuroendocrine TumorLast Updated:September 18, 2012Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.